18 patents
Utility
Modified relaxin polypeptides and their uses
17 Oct 23
Modified relaxin polypeptides and their uses thereof are provided.
Vadim Kraynov, Nick Knudsen, Amha Hewet, Kristine De Dios, Jason Pinkstaff, Lorraine Sullivan
Filed: 3 Mar 22
Utility
Antibody peptide conjugates that have agonist activity at both the glucagon and glucagon-like peptide 1 receptors
3 Oct 23
Described are antibody peptide conjugates (APCs) comprising an antibody conjugated to a peptide analog of glucagon, which have been modified to be resistant to cleavage and inactivation by dipeptidyl peptidase IV (DPP-IV) and to increase in vivo half-life of the peptide analog while enabling the peptide analog to have agonist activity at the glucagon (GCG) receptor and the glucagon-like peptide 1 (GLP-1) receptor and the use of such APCs for treatment of metabolic disorders such as diabetes, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and obesity.
Paul E. Carrington, Grigori Ermakov, Robert M. Garbaccio, Wolfgang Seghezzi, Elisabetta Bianchi, Federica Orvieto, Dennis Gately, Nick Knudsen, Anthony Manibusan
Filed: 27 Aug 20
Utility
Porcine G-CSF variants and their uses
14 Feb 23
The present invention relates to variants of porcine granulocyte colony stimulating factor (pG-CSF).
Peter Connor Canning, Nickolas Knudsen, Md Harunur Rashid
Filed: 10 Oct 18
Utility
Modified bovine G-CSF polypeptides and their uses
3 Jan 23
Modified bovine G-CSF polypeptides and uses thereof are provided.
Anna-Maria A. Hays Putnam, Nick Knudsen, Thea Norman, Alan Koder, Vadim Kraynov, Lillian Skidmore, Peter C. Canning
Filed: 19 Oct 18
Utility
Antibody drug conjugate for anti-inflammatory applications
29 Nov 22
Antibody drug conjugates (ADCs) comprising an antibody conjugated to an anti-inflammatory therapeutic agent via a phosphate-based linker with tunable extracellular and intracellular stability are described.
Philip E. Brandish, Robert M. Garbaccio, Jeffrey Kern, Linda Liang, Sanjiv Shah, Dennis Zaller, Andrew Beck, Dennis Gately, Nick Knudsen, Anthony Manibusan, Jianing Wang, Ying Sun
Filed: 30 Sep 16
Utility
Anti-CD70 antibody drug conjugates
4 Oct 22
This invention relates to anti-CD70 antibodies and antibody drug conjugates comprising at least one non-naturally-encoded amino acid.
Richard S Barnett, Nick Knudsen, Ying Sun, Sandra Biroc, Timothy Buss, Tsotne Javahishvili, Damien Bresson, Shailaja Srinagesh, Amha Hewet, Jason Pinkstaff
Filed: 18 Dec 18
Utility
Nucleic acids encoding modified relaxin polypeptides
13 Sep 22
Modified relaxin polypeptides and their uses thereof are provided.
Vadim Kraynov, Nick Knudsen, Amha Hewet, Kristine De Dios, Jason Pinkstaff, Lorraine Sullivan
Filed: 28 May 20
Utility
Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives
23 Aug 22
Disclosed herein are non-natural amino acids and dolastatin analogs that include at least one non-natural amino acid, and methods for making such non-natural amino acids and polypeptides.
Zhenwei Miao, Kyle Atkinson, Sandra Biroc, Timothy Buss, Melissa Neal, Vadim Kraynov, Robin Marsden, Jason Pinkstaff, Lillian Skidmore, Ying Sun, Agnieszka Szydlik, Delia Ianina Lopez De Valenta
Filed: 5 Jan 21
Utility
Methods of treating heart failure and fibrotic disorders using modified relaxin polypeptides
26 Apr 22
Modified relaxin polypeptides and their uses thereof are provided.
Vadim Kraynov, Nick Knudsen, Amha Hewet, Kristine De Dios, Jason Pinkstaff, Lorraine Sullivan
Filed: 27 May 20
Utility
Pegylated porcine interferon and methods of use thereof
30 Mar 21
Disclosed herein are porcine interferon alpha variants (pIFN-α) comprising a synthetic amino acid at select locations in pIFN-α and a one or two amino acid insertion in the N-terminus after removal of the signal peptide.
Peter Connor Canning, Nickolas Knudsen, Lillian Skidmore
Filed: 16 Jun 17
Utility
Modified FGF-21 polypeptides and their uses
30 Mar 21
Modified FGF-21 polypeptides and uses thereof are provided.
Thomas P. Cujec, Roberto Mariani, Anna-Maria A. Hays Putnam, William M. Keefe, Nick Knudsen, Lillian Skidmore, Jason Pinkstaff, Vadim Kraynov
Filed: 17 Jun 19
Utility
Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives
23 Mar 21
Disclosed herein are non-natural amino acids and dolastatin analogs that include at least one non-natural amino acid, and methods for making such non-natural amino acids and polypeptides.
Zhenwei Miao, Kyle Atkinson, Sandra Biroc, Timothy Buss, Melissa Neal, Vadim Kraynov, Robin Marsden, Jason Pinkstaff, Lillian Skidmore, Ying Sun, Agnieszka Szydlik, Delia Ianina Lopez De Valenta
Filed: 12 Sep 17
Utility
Antibody peptide conjugates that have agonist activity at both the glucagon and glucagon-like peptide 1 receptors
12 Oct 20
Described are antibody peptide conjugates (APCs) comprising an antibody conjugated to a peptide analog of glucagon, which have been modified to be resistant to cleavage and inactivation by dipeptidyl peptidase IV (DPP-IV) and to increase in vivo half-life of the peptide analog while enabling the peptide analog to have agonist activity at the glucagon (GCG) receptor and the glucagon-like peptide 1 (GLP-1) receptor and the use of such APCs for treatment of metabolic disorders such as diabetes, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and obesity.
Paul Carrington, Grigori Ermakov, Robert M. Garbaccio, Wolfgang Seghezzi, Elisabetta Bianchi, Federica Orvieto, Dennis Gately, Nick Knudsen, Anthony Manibusan
Filed: 3 Oct 16
Utility
Prostate-specific membrane antigen antibody drug conjugates
12 Oct 20
This invention relates to prostate-specific membrane antigen (PSMA) antibodies and antibody drug conjugates comprising at least one non-naturally-encoded amino acid.
Richard S. Barnett, Feng Tian, Anna-Maria A. Hays Putnam, Marco Gymnopoulos, Nick Knudsen, Andrew Beck, Ying Sun
Filed: 6 Jun 13
Utility
Methods of treatment using modified relaxin polypeptides comprising a non-naturally encoded amino acid
24 Aug 20
Modified relaxin polypeptides and their uses thereof are provided.
Vadim Kraynov, Nick Knudsen, Amha Hewet, Kristine De Dios, Jason Pinkstaff, Lorraine Sullivan
Filed: 25 Feb 19
Utility
Modified relaxin polypeptides comprising a non-naturally encoded amino acid in the A chain
6 Jul 20
Modified relaxin polypeptides and their uses thereof are provided.
Vadim Kraynov, Nick Knudsen, Amha Hewet, Kristine De Dios, Jason Pinkstaff, Lorraine Sullivan
Filed: 29 Mar 18
Utility
Phosphate based linkers for intracellular delivery of drug conjugates
3 Feb 20
Phosphate-based linkers with tunable stability for intracellular delivery of drug conjugates are described.
Robert M. Garbaccio, Jeffrey Kern, Philip E. Brandish, Sanjiv Shah, Linda Liang, Ying Sun, Jianing Wang, Nick Knudsen, Andrew Beck, Anthony Manibusan, Dennis Gately
Filed: 29 Mar 15
Utility
Non-natural amino acid replication-dependent microorganisms and vaccines
30 Sep 19
Compositions and methods of producing vaccines, including methods wherein whole organism vaccines are provided with limited replication abilities, thereby increasing vaccine safety and efficacy, through the use of non-natural, unnatural, or non-naturally encoded amino acids.
Feng Tian, Brad Hehli
Filed: 8 Aug 13
- Prev
- 1
- Next
Patents are sorted by USPTO publication date, most recent first